About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Increased cost sharing by patients results in the reduced use of prescription drugs. A retrospective study by the authors found that diabetic patients did not adhere to their regimens, and thus did not meet target treatment goals, if they were required to pay part of the cost of their medications.
John Barron, PharmD; Peter Wahl, MLA, MS; Maxine Fisher, PhD; and Craig Plauschinat, PharmD, MPH
Health Care and Law
Immunizations can protect large numbers of people in a community — even those who have not been inoculated. However, the reluctance of growing numbers of people to receive vaccinations for themselves and their children raises the risk of reducing “herd immunity,” which can lead to widespread infection in a population.
Robert I. Field, JD, MPH, PhD
Every citizen 18 years of age and older in Massachusetts is required to obtain health insurance. This article describes the state’s progress and discusses how it might influence proposals for health care reform offered by the two presidential candidates.
Therapies covered include balsalazide (Colazal) and infliximab (Remicade) for ulcerative colitis; infliximab/methotrexate and certolizumab pegol (Cimzia) for Crohn’s disease; and glucose-lowering strategies, as well as a combination of sitagliptin (Januvia) and metformin (Glucophage), for diabetes.
Topics include clevidipine (Cleviprex) for reducing blood pressure; repaglinide/ metformin (PrandiMet) for improving glycemic control; and difluprednate ophthalmic emulsion (Durezol) for treating inflammation and pain after ocular surgery.
Marvin M. Goldenberg, PhD, RPh, MS
David Nash, MD, MBA, describes eight emerging technology trends that are transforming markets and businesses and may soon be coming to a P&T committee near you.
David Nash, MD, MBA
In part 2 of a two-part article, Matthew Grissinger, RPh, FASCP, explains how P&T committee members can be negatively influenced when they encounter myths and misconceptions about formularies.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses how taxpayers might be able to save almost $90 million per year if a bill were passed to eliminate the inflated prices for Part D Medicare benefits.
From Cleviprex to Xenazine, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.
Dr. Egerton reviews ixabepilone (Ixempra) for metastatic or locally advanced breast cancer.
Nancy Egerton, PharmD, BCOP